IMRX vs. XLO, NBRV, SNSE, RMTI, LEXX, NXTC, HCWB, UNCY, CARA, and OCUP
Should you be buying Immuneering stock or one of its competitors? The main competitors of Immuneering include Xilio Therapeutics (XLO), Nabriva Therapeutics (NBRV), Sensei Biotherapeutics (SNSE), Rockwell Medical (RMTI), Lexaria Bioscience (LEXX), NextCure (NXTC), HCW Biologics (HCWB), Unicycive Therapeutics (UNCY), Cara Therapeutics (CARA), and Ocuphire Pharma (OCUP). These companies are all part of the "pharmaceutical preparations" industry.
Xilio Therapeutics (NASDAQ:XLO) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment, dividends and community ranking.
Immuneering received 13 more outperform votes than Xilio Therapeutics when rated by MarketBeat users. However, 73.33% of users gave Xilio Therapeutics an outperform vote while only 61.54% of users gave Immuneering an outperform vote.
Xilio Therapeutics has a beta of -0.13, suggesting that its stock price is 113% less volatile than the S&P 500. Comparatively, Immuneering has a beta of -0.6, suggesting that its stock price is 160% less volatile than the S&P 500.
Immuneering has higher revenue and earnings than Xilio Therapeutics. Immuneering is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.
Immuneering has a consensus price target of $13.50, indicating a potential upside of 754.43%. Given Xilio Therapeutics' higher possible upside, analysts clearly believe Immuneering is more favorable than Xilio Therapeutics.
54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 4.6% of Xilio Therapeutics shares are owned by insiders. Comparatively, 25.0% of Immuneering shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Xilio Therapeutics' return on equity of -55.79% beat Immuneering's return on equity.
In the previous week, Xilio Therapeutics had 3 more articles in the media than Immuneering. MarketBeat recorded 6 mentions for Xilio Therapeutics and 3 mentions for Immuneering. Xilio Therapeutics' average media sentiment score of -0.22 beat Immuneering's score of -0.34 indicating that Immuneering is being referred to more favorably in the news media.
Summary
Immuneering beats Xilio Therapeutics on 11 of the 16 factors compared between the two stocks.
Get Immuneering News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immuneering Competitors List
Related Companies and Tools
